Long-term use of somatostatin analogue SMS 201-995 in the treatment of hypoglycaemia due to nesidioblastosis.
An infant presented with hypoglycaemia secondary to nesidioblastosis. Subtotal pancreatectomy failed to prevent recurrent post-operative hypoglycaemia. Subcutaneous somatostatin analogue (SMS 201-995) was shown to increase the blood concentrations of glucose and B-hydroxybutyrate while lowering serum insulin levels. Regular use of somatostatin analogue was helpful in long term management without causing significant side effects.
D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy* / Q000209:etiology; D007223:Infant; D007231:Infant, Newborn; D007279:Injections, Subcutaneous; D015282:Octreotide; D010180:Pancreatectomy; D010182:Pancreatic Diseases / Q000150:complications* / Q000628:therapy; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors
D013004:Somatostatin; D015282:Octreotide